May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Single-Session Photodynamic Therapy Combined with Intravitreal Bevacizumab for Retinal Angiomatous Proliferation
Author Affiliations & Notes
  • G. Lo Giudice
    Ophthalmology, Sant'Antonio Hospital, Padova, Italy
  • M. Gismondi
    Ophthalmology, Conegliano Hospital, Conegliano, Italy
  • V. de Belvis
    Ophthalmology, University of Padova, Padova, Italy
  • V. Maritan
    Ophthalmology, Conegliano Hospital, Conegliano, Italy
  • G. Prosdocimo
    Ophthalmology, Conegliano Hospital, Conegliano, Italy
  • Footnotes
    Commercial Relationships  G. Lo Giudice, None; M. Gismondi, None; V. de Belvis, None; V. Maritan, None; G. Prosdocimo, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2158. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Lo Giudice, M. Gismondi, V. de Belvis, V. Maritan, G. Prosdocimo; Single-Session Photodynamic Therapy Combined with Intravitreal Bevacizumab for Retinal Angiomatous Proliferation. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2158. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the efficacy of combined therapy consisting of single-session photodynamic therapy (PDT) and intravitreal bevacizumab (IVB) for the treatment of retinal angiomatous proliferation (RAP) secondary to age-related macular degeneration.

Methods: : In a retrospective, nonrandomized, interventional case series, 8 eyes of eight patients with RAP underwent indocyanine green angiography (ICGA) guided a single-session PDT with verteporfin followed by intravitreal bevacizumab (1.25 mg/0.05 ml) within a 7-day interval. All patients were naive to treatment. Complete ocular examination including best corrected visual acuity (BCVA), fluorescein angiography (FA), ICGA, optical coherence tomography (OCT), were performed at baseline and each follow-up visit. All patients received three consecutive monthly intravitreal injections of bevacizumab. Thereafter, retreatment with only bevacizumab was performed if one of the following changes were observed: a loss of five letters in conjunction with fluid in the macula as detected by OCT, an increase in OCT central retinal thickness of at least 100 µm, new-onset of CNV, new macular hemorrhage, or persistent macular fluid detected by both OCT and FA/ICGA at least one month after the previous injection of avastin. Interval data were analyzed statistically at 3, 6 and 9 months follow-up.

Results: : This series included eight eyes of eight patients with mean age 67.6 ± 7.2 years. All patients had 9 months of follow-up. Mean BCVA prior to treatment was 0.21 ± 0.09 logMAR which improved to 0.41 ± 0.20 logMAR (P = 0.05), 0.40± 0.15 logMAR, and 0.42 ± 0.14 logMAR (P = 0.005) after 12 weeks, 6 and 9 months respectively. Mean pretreatment central macular thickness (CMT) was 371.9 ± 194.3µm which was significantly reduced to 140 ± 59.3µm , 162.8 ± 77.8µm (P = 0.028) and 162 ± 74.1µm 3, 6 and 9 months after initial treatment respectively (P <0.0001). Two patients developed recurrent leakage after three to six months, which settled completely after repeat IVB.

Conclusions: : Sequenced combined treatment with single-session PDT and IVB may be useful in treating RAP, reducing or eliminating retinal edema, and improving visual acuity. Further investigations are warranted to outline the appropriate treatment paradigm for combination therapy.

Keywords: retinal neovascularization • vascular endothelial growth factor 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.